ライフサイエンスコーパス: malignant mesothelioma

1 phase III clinical trials as a treatment for malignant mesothelioma.

2 as a result of Dishevelled overexpression in malignant mesothelioma.

3 cal trials for the treatment of unresectable malignant mesothelioma.

4 ng pathways may be a strategy for therapy of malignant mesothelioma.

5 e the most frequent genetic lesions in human malignant mesothelioma.

6 beta gene (Ad.muIFN-beta) in mouse models of malignant mesothelioma.

7 trated frequent deletions from 15q11.1-15 in malignant mesothelioma.

8 n highly differentiated breast carcinoma and malignant mesothelioma.

9 stos is a major factor in the development of malignant mesothelioma.

10 d mesothelial cells, the progenitor cells of malignant mesothelioma.

11 n malignancies of nonneuronal origin such as malignant mesothelioma.

12 iation therapy and subsequent development of malignant mesothelioma.

13 ferroptosis in an orthotopic mouse model of malignant mesothelioma.

14 athways and eventual sporadic development of malignant mesothelioma.

15 placebo in patients with previously treated malignant mesothelioma.

16 in patients with previously treated advanced malignant mesothelioma.

17 predispose to several cancers, in particular malignant mesothelioma.

18 shown promising results for the treatment of malignant mesothelioma.

19 ibitor, SM16, in the AB12 syngeneic model of malignant mesothelioma.

20 a rare and clinically distinct entity among malignant mesotheliomas.

21 (+/-) knockout mice with asbestos to induce malignant mesotheliomas.

22 ism in the etiology of the majority of human malignant mesotheliomas.

23 ven of 15 patients had histologically proven malignant mesotheliomas (10 epithelial, 1 sarcomatoid).

24 3 eligible patients with suspected or proven malignant mesothelioma, 41 could be included in the data

25 on Criteria in Solid Tumours version 1.1 for malignant mesothelioma, a predicted life expectancy of a

26 Human malignant mesotheliomas accumulate multiple somatic gene

27 multicenter clinical registration trials for malignant mesothelioma: amatuximab in the first-line set

28 lly blocking HMGB1, may decrease the risk of malignant mesothelioma among asbestos-exposed cohorts.

29 ates many of the molecular features of human malignant mesothelioma and has significant implications

30 tand the significance of NF2 inactivation in malignant mesothelioma and identify tumor suppressor gen

31 lasms of non-neuroectodermal origin, such as malignant mesothelioma and melanoma.

32 ency only in select human cancers, including malignant mesothelioma and meningioma.

33 or pathways critical for the pathogenesis of malignant mesothelioma and other NF2-related malignancie

34 y expressed in many human cancers, including malignant mesothelioma and pancreatic, ovarian, and lung

35 r significant potential for the treatment of malignant mesothelioma and possibly other cancers.

36 tion of asbestos-exposed individuals develop malignant mesothelioma, and because mesothelioma cluster

37 Nf2, and Cdkn2a results in rapid, aggressive malignant mesotheliomas, and that deletion of Bap1 contr

38 clinical characteristics of epithelial type malignant mesothelioma are distinct from those of biphas

39 ovide greater efficacy than monotherapies in malignant mesothelioma are ongoing.

40 New therapeutic strategies for malignant mesothelioma are urgently needed.

41 Malignant mesotheliomas are highly aggressive tumors usu

42 The clinicopathologic characteristics of malignant mesotheliomas arising in these patients have n

43 ogenic tyrosine kinase receptor expressed in malignant mesothelioma as well as in a variety of cancer

44 rwent treatment for pathologically confirmed malignant mesothelioma at Brigham and Women's Hospital a

45 nical use for patients with glioblastoma and malignant mesothelioma, based on the principle of using

46 aluated telomerase activity in seven primary malignant mesothelioma biopsies and matched lung specime

47 with asbestos in the development of diffuse malignant mesothelioma, but its precise role in the path

48 Malignant mesothelioma causes profound morbidity and nea

49 ranscriptome in human normal mesothelial and malignant mesothelioma cell lines exposed or not exposed

50 Analysis of a panel of malignant mesothelioma cell lines reveals a strong corre

51 uctase inhibitor, induced apoptosis in human malignant mesothelioma cell lines.

52 luate if talc directly effects cell death of malignant mesothelioma cells (MMC) or normal pleural mes

53 m for the maintenance of EphB4-expression in malignant mesothelioma cells and other IGF-II-secreting

54 demonstrate that EphB4 protein expression in malignant mesothelioma cells depend upon a degradation r

55 Here we show that EphB4 expression in malignant mesothelioma cells is markedly decreased upon

56 Taken together, our findings indicate that malignant mesothelioma cells rely on HMGB1, and they off

57 Malignant mesothelioma cells strongly expressed HMGB1 an

58 Human malignant mesothelioma cells supported the growth of HSV

59 at HMGB1 establishes an autocrine circuit in malignant mesothelioma cells that influences their proli

60 horage-independent growth of HMGB1-secreting malignant mesothelioma cells was inhibited in vitro by t

61 approved therapy for glioblastoma (GBM) and malignant mesothelioma, employ noninvasive application o

62 Ovarian cancer and malignant mesothelioma frequently express both mesotheli

63 otheliomas from Nf2 (+/-) mice and in 50% of malignant mesotheliomas from asbestos-exposed WT mice.

64 n, was observed in all nine asbestos-induced malignant mesotheliomas from Nf2 (+/-) mice and in 50% o

65 As in the human disease counterpart, malignant mesotheliomas from the Nf2 (+/-) mice also sho

66 with a median survival of only 12 weeks, and malignant mesotheliomas from these mice were consistentl

67 RNA-seq analysis of malignant mesotheliomas from triple-CKO mice revealed en

68 Samples of malignant mesotheliomas, gliomas, sarcomas, and lymphore

69 Malignant mesothelioma has been linked to asbestos expos

70 treatment of non-small cell lung cancer and malignant mesothelioma, has adverse effects including ne

71 either Nf2 or Cdkn2a to drive development of malignant mesothelioma in approximately 20% of double-CK

72 ibers may significantly increase the risk of malignant mesothelioma in genetically predisposed indivi

73 Notably, we also observed malignant mesotheliomas in two Bap1-mutant mice, but not

74 Cdkn2a, or Nf2 alone gave rise to few or no malignant mesotheliomas, inactivation of Bap1 cooperated

75 tumors unrelated to the NF2 syndrome such as malignant mesothelioma, indicating a broader role for th

76 Malignant mesothelioma is a cancer with poor prognosis a

77 Malignant mesothelioma is a deadly disease with limited

78 Malignant mesothelioma is a rare tumour caused by asbest

79 Pleural malignant mesothelioma is a therapy-resistant cancer aff

80 Human malignant mesothelioma is an aggressive and highly letha

81 Malignant mesothelioma is an aggressive and lethal pleur

82 Malignant mesothelioma is an aggressive cancer largely a

83 Malignant mesothelioma is an aggressive neoplastic proli

84 Malignant mesothelioma is one of the very few extrarenal

85 s used worldwide, but its capacity to induce malignant mesothelioma is still debated.

86 Malignant mesothelioma is strongly associated with asbes

87 Genetically stratified therapy for malignant mesothelioma is unavailable.

88 benign and malignant tumor types, including malignant mesothelioma, melanoma, and kidney carcinoma.

89 Malignant mesothelioma (MESO) is a highly aggressive can

90 the causal relationship established between malignant mesothelioma (MM) and asbestos exposure, the e

91 Malignant mesothelioma (MM) arising in the peritoneal ca

92 We have generated mouse models of malignant mesothelioma (MM) based upon disruption of the

93 ays, to fine map genomic imbalances in human malignant mesothelioma (MM) cell lines derived from prim

94 identify chromosomal imbalances in 24 human malignant mesothelioma (MM) cell lines derived from untr

95 e expression changes in rat asbestos-induced malignant mesothelioma (MM) cells were investigated by d

96 nt study, we determined IL-8 levels in human malignant mesothelioma (MM) effusions and congestive hea

97 Malignant mesothelioma (MM) is a cancer of the lining of

98 Malignant mesothelioma (MM) is a relatively rare but dev

99 Malignant mesothelioma (MM) is an aggressive cancer prim

100 Malignant mesothelioma (MM) is an aggressive malignancy,

101 Malignant mesothelioma (MM) is an aggressive tumor with

102 Malignant mesothelioma (MM) is an asbestos-induced cance

103 Malignant mesothelioma (MM) is associated with asbestos

104 -like mineral, causes unprecedented rates of malignant mesothelioma (MM) mortality in some Turkish vi

105 Malignant mesothelioma (MM) of pleura is an aggressive a

106 the effect of the micronutrient selenium on malignant mesothelioma (MM) progression, we cultured fou

107 ls of naturally occurring asbestos (NOA) and malignant mesothelioma (MM) risk.

108 rotein 1 gene (BAP1) mutations contribute to malignant mesothelioma (MM) susceptibility.

109 th unresectable and histologically confirmed malignant mesothelioma (MM) were eligible.

110 Gemcitabine plus cisplatin is active in malignant mesothelioma (MM), although single-arm phase I

111 ng to the development and chemoresistance of malignant mesothelioma (MM), an aggressive asbestos-asso

112 Cancers of the mesothelium, such as malignant mesothelioma (MM), historically have been attr

113 Malignant mesothelioma (MM), is an intractable disease w

114 tion of subjects exposed to asbestos develop malignant mesothelioma (MM), suggesting that additional

115 susceptible to accelerated asbestos-induced malignant mesothelioma (MM).

116 a tumor suppressor frequently inactivated in malignant mesothelioma (MM).

117 Asbestos is the main cause of human malignant mesothelioma (MM).

118 Among malignant mesotheliomas (MM), the sarcomatoid subtype is

119 We compared the methylation profile of 66 malignant mesotheliomas (MMs) and 40 lung adenocarcinoma

120 Malignant mesotheliomas (MMs) are aggressive tumors deri

121 Malignant mesotheliomas (MMs) are very aggressive tumors

122 Our previous cytogenetic studies of malignant mesotheliomas (MMs) revealed losses from 6q15-

123 Malignant mesothelioma (MpM) is an aggressive, invariabl

124 onse in patients with chemotherapy-resistant malignant mesothelioma of the pleura or peritoneum.

125 Malignant mesothelioma onset was rapid in triple-CKO mic

126 Survival from malignant mesothelioma, particularly pleural mesotheliom

127 ications for the further characterization of malignant mesothelioma pathogenesis and preclinical test

128 that cooperate with NF2 loss of function in malignant mesothelioma pathogenesis, we treated Nf2 (+/-

129 Accordingly, HMGB1 levels in malignant mesothelioma patient sera were higher than tha

130 orted an association between pleural diffuse malignant mesothelioma (PDMM) and chest radiation for ly

131 The inability to forecast outcomes for malignant mesothelioma prevents clinicians from providin

132 d for other diseases, including lung cancer, malignant mesothelioma, pulmonary inflammation, surfacta

133 s with advanced, recurrent ovarian cancer or malignant mesothelioma received anetumab ravtansine at t

134 response predicts survival in patients with malignant mesothelioma receiving high-dose pembrolizumab

135 response predicts survival in patients with malignant mesothelioma receiving high-dose pembrolizumab

136 Malignant mesothelioma remains an incurable disease for

137 analyses were also done on a series of human malignant mesothelioma samples.

138 opriate treatment for selected patients with malignant mesothelioma selected using a revised staging

139 equent losses of chromosome 1p21-22 in human malignant mesothelioma, suggesting that the loss or inac

140 is project was to evaluate, in patients with malignant mesothelioma, the relationship between inherit

141 Except for malignant mesotheliomas, the role of NF2 mutation or ina

142 developed a multicellular spheroid model of malignant mesothelioma to investigate molecular mechanis

143 suggesting a novel therapeutic approach for malignant mesothelioma treatment.

144 f2 (+/-) mice exhibited markedly accelerated malignant mesothelioma tumor formation compared with asb

145 ows potent activity against established AB12 malignant mesothelioma tumors using an immune-mediated m

146 mor recurrence after resection of bulky AB12 malignant mesothelioma tumors.

147 Remarkably, similar to human malignant mesotheliomas, tumors from Nf2 (+/-) mice show

148 ows promise in an ongoing clinical trial for malignant mesothelioma using direct pleural infusion.

149 ensity loss of heterozygosity analysis of 46 malignant mesotheliomas, using 26 polymorphic microsatel

150 (-/-) malignancies in their lifetime, mostly malignant mesothelioma, uveal melanoma, and so on.

151 O mice, and a high incidence (22/26, 85%) of malignant mesotheliomas was observed in Bap1;Nf2;Cdkn2a

152 Patients with histologically confirmed malignant mesothelioma were evaluated for inherited muta

153 Four cases of malignant mesothelioma were observed following Hodgkin's

154 imary tumor specimens and cell lines from 50 malignant mesotheliomas were examined for loss of hetero

155 and is present in the serum of patients with malignant mesothelioma, which could negatively affect th

156 ents with unresectable pleural or peritoneal malignant mesothelioma who had progressed after one or t

157 ival for patients with pleural or peritoneal malignant mesothelioma who have progressed following pla

158 nt that might be beneficial to patients with malignant mesothelioma who have progressed on first-line

159 GB1 inhibition in vivo reduced the growth of malignant mesothelioma xenografts in severe-combined imm

160 strongly associated with the development of malignant mesothelioma, yet the mechanistic basis of thi